AU2022205969A1 - Use of a kras g12c inhibitor in treating cancers - Google Patents

Use of a kras g12c inhibitor in treating cancers Download PDF

Info

Publication number
AU2022205969A1
AU2022205969A1 AU2022205969A AU2022205969A AU2022205969A1 AU 2022205969 A1 AU2022205969 A1 AU 2022205969A1 AU 2022205969 A AU2022205969 A AU 2022205969A AU 2022205969 A AU2022205969 A AU 2022205969A AU 2022205969 A1 AU2022205969 A1 AU 2022205969A1
Authority
AU
Australia
Prior art keywords
subject
mutation
kras
positive
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022205969A
Other languages
English (en)
Other versions
AU2022205969A9 (en
Inventor
Agnes L. ANG
Haby HENARY
Gataree Ngarmchamnanrith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2022205969A1 publication Critical patent/AU2022205969A1/en
Publication of AU2022205969A9 publication Critical patent/AU2022205969A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2022205969A 2021-01-08 2022-01-07 Use of a kras g12c inhibitor in treating cancers Pending AU2022205969A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163135449P 2021-01-08 2021-01-08
US63/135,449 2021-01-08
US202163189625P 2021-05-17 2021-05-17
US63/189,625 2021-05-17
PCT/US2022/011673 WO2022150628A1 (en) 2021-01-08 2022-01-07 Use of a kras g12c inhibitor in treating cancers

Publications (2)

Publication Number Publication Date
AU2022205969A1 true AU2022205969A1 (en) 2023-07-06
AU2022205969A9 AU2022205969A9 (en) 2024-02-08

Family

ID=80222156

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022205969A Pending AU2022205969A1 (en) 2021-01-08 2022-01-07 Use of a kras g12c inhibitor in treating cancers

Country Status (8)

Country Link
US (1) US20240091230A1 (cg-RX-API-DMAC7.html)
EP (2) EP4274579A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024502446A (cg-RX-API-DMAC7.html)
AU (1) AU2022205969A1 (cg-RX-API-DMAC7.html)
CA (1) CA3206523A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023007918A (cg-RX-API-DMAC7.html)
TW (1) TWI906448B (cg-RX-API-DMAC7.html)
WO (1) WO2022150628A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
PE20260006A1 (es) 2023-01-26 2026-01-06 Arvinas Operations Inc Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA127968C2 (uk) 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
EP3738593A1 (en) * 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
EP3972973A1 (en) 2019-05-21 2022-03-30 Amgen Inc. Solid state forms

Also Published As

Publication number Publication date
MX2023007918A (es) 2023-07-13
WO2022150628A1 (en) 2022-07-14
TWI906448B (zh) 2025-12-01
EP4650006A3 (en) 2026-01-14
EP4274579A1 (en) 2023-11-15
US20240091230A1 (en) 2024-03-21
EP4650006A2 (en) 2025-11-19
JP2024502446A (ja) 2024-01-19
AU2022205969A9 (en) 2024-02-08
TW202241442A (zh) 2022-11-01
CA3206523A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
US20240091230A1 (en) Use of kras g12c inhibitor in treating cancers
Ma et al. A phase II trial of neoadjuvant MK-2206, an AKT inhibitor, with anastrozole in clinical stage II or III PIK3CA-mutant ER-positive and HER2-negative breast cancer
ES3052701T3 (en) Sotorasib for use in the treatment of cancer
KR20210064252A (ko) Cdc7 억제제를 포함하는 암의 치료 방법
US20260069593A1 (en) Methods for treating cancer
JP2024510612A (ja) ソトラシブ投与レジメン
WO2023049363A1 (en) Sotorasib and afatinib for treating cancer comprising a kras g12c mutation
KR20230078705A (ko) 항-her2 항체와 병용된 투카티닙으로 her2 변형에 의해 유도된 고형 종양을 치료하는 방법
JP2026053570A (ja) Kras g12c変異を含む癌を治療するためのソトラシブ及びegfr抗体
JP2022532597A (ja) Chk1阻害剤を使用してがんを治療する方法
Johnson et al. 8LBA Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
JP2025508399A (ja) 脳がんの処置のためのニラパリブの使用
EP4694891A1 (en) Dosage regimen for sotorasib/carboplatin/pemetrexed in cancer treatment
HK40126893A (en) Dosage regimen for sotorasib/carboplatin/pemetrexed in cancer treatment
WO2024015360A1 (en) Methods of treating cancer
Langer Highlights in NSCLC from the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.
HK40102675A (en) Sotorasib dosing regimen
EA051386B1 (ru) Соторасиб и антитело к egfr для лечения рака, предусматривающего мутацию kras g12c

Legal Events

Date Code Title Description
SREP Specification republished